NCIA Event, June 13: Paul Coble Moderates Panel on Testing and Labeling for “Minor Cannabinoid” Products

09 Jun NCIA Event, June 13: Paul Coble Moderates Panel on Testing and Labeling for “Minor Cannabinoid” Products

We are pleased to announce Paul Coble as a panelist moderator for the National Cannabis Industry Association (NCIA) webinar event this coming Tuesday, Jun 13, 2023 at 12:00 PM. The event is titled, From Lab to Label: Safegaurding Consumers in the Cannabinoid Product Landscape.  This is the third webinar in the NCIA’s 5-part series on minor, novel, and synthetic cannabinoids like CBG, CBN, THCv, and many others.

Paul is an intellectual property attorney and software startup founder with a deep background in cannabis science and technology. He studied molecular biology and chemistry as an undergraduate before turning to the study of law. Paul is the former chair and current chair emeritus of the NCIA’s Cannabis Manufacturing Committee.

In this event, Paul will moderate a conversation on a popular new consumer product category: products containing the various cannabinoids other than THC and CBD. With so many different label content requirements from state to state for consumer products containing cannabinoids, the lack of consistency can lead to potential risks to the end consumer. This is especially true when the majority of cannabinoid product manufacturers are dependent on third-party data during product manufacturing and compliance testing. This interdependence between testing laboratories and product manufacturers makes it all the more important that label content requirements are: 1) achievable from a manufacturing standpoint, 2) consistent with public health and safety goals and 3) not overly burdensome for regulators.

This webinar features a panel of experts who will speak about the current state of America’s somewhat-monitored cannabinoid-product marketplace, and touch on several of the issues related to cannabinoid quantification, cannabinoid content declarations, and label claim verification and how these relate to consumer safety.

Learning Objectives:

• Learn about the potential risks associated with untested, unlabeled products
• Learn best practices from industry professionals to ‘futureproof’ your business no matter what type of cannabinoids you’re working with
• Understand the nuances with label content compliance and implications on label claims

You can register for this event HERE.